Endpoints
NeuroRx Announces ZYESAMI™ Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19
NeuroRx
PR-M03-21-005Mar 29, 2021
COVID-19 Clinical Trials
NeuroRx and Relief Therapeutics Announce Continuation of RLF-100 Trial for the Treatment of COVID-19 Respiratory Failure
NeuroRx
PR-M11-20-005Nov 06, 2020